Latest news

Thumbnail image for MHRA bans valproate without pregnancy prevention programme

MHRA bans valproate without pregnancy prevention programme

The Medicines and Healthcare products Regulatory Agency (MHRA) has changed the licence for valproate medicines, so that they can no longer be prescribed to females of child-bearing age unless they are on the pregnancy prevention programme.

24th April 2018

Thumbnail image for EU reviewing MSD’s Keytruda/chemo combo

EU reviewing MSD’s Keytruda/chemo combo

European regulators have kicked off a review of MSD’s Keytruda/pemetrexed combination for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).

24th April 2018

Thumbnail image for AZ lung cancer combo fails to hit targets

AZ lung cancer combo fails to hit targets

A combination of immunotherapy drugs being tested by AstraZeneca in the third-line setting in patients with lung cancer has failed to slow disease progression or extend survival.

24th April 2018

Thumbnail image for Fresenius pulls out of $4.3bn Akorn merger

Fresenius pulls out of $4.3bn Akorn merger

German healthcare firm Fresenius Kabi is walking away from a $4.3-billion merger with US generics group Akorn, claiming that the latter has failed to fulfill several closing conditions.

23rd April 2018

Thumbnail image for CHMP rejects AB Science’s ALS drug

CHMP rejects AB Science’s ALS drug

AB Science’s share price has taken a hit after European Medicine Agency's advisors rejected approval of masitinib for amyotrophic lateral sclerosis.

23rd April 2018

Thumbnail image for Shire turns down Takeda’s advances

Shire turns down Takeda’s advances

Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion.

20th April 2018

Thumbnail image for FDA advisors back approval of GW’s Epidiolex

FDA advisors back approval of GW’s Epidiolex

As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

20th April 2018

Thumbnail image for US widens use of AZ’ Tagrisso in lung cancer

US widens use of AZ’ Tagrisso in lung cancer

AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.

20th April 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download